There is a moment in every advisory board where you can feel it. The room goes quiet, the questions get safer, and whatever insight you came for starts slipping away. It does not happen because the people are not smart. Pharma advisory boards are usually packed with brilliant clinicians and sharp thinkers. The problem is that most boards are designed to inform, not to discover. And that is a structural failure, not a human one. Because structure is everything. The questions you ask, the people you invite, the space you create for challenge – these are not logistical details. They are the board.
Start with the question, not the slides
If your advisory board opens with 40 slides, you have already lost the room. The best boards begin with a clear, slightly uncomfortable question – one that does not have an obvious answer, and one your internal team cannot solve alone. Something like: why are patients not progressing through this pathway? Where does this product genuinely not fit? What are we still getting wrong? If the question feels too neat, it probably is. And if it only makes sense from one vantage point inside your organisation, your advisors will feel that the moment they walk in. Pressure-testing the question before you enter the room matters more than most teams ever realise.
The usual suspects are not enough
It is tempting to invite the KOLs who know your data, like your team, and understand your story. But if everyone in the room already agrees, you are not running an advisory board. You are running a validation exercise and calling it something else. There is a subtler version of this problem too: when every expert has followed a similar career path, works in similar centres, and sees similar patients, you do not get insight. You get echo. The way a clinician in a large academic centre thinks about a treatment pathway can be entirely different from someone working in a district hospital. The challenges in one country may barely exist in another. Perspectives shaped by different experiences often surface gaps that specialists, however expert, simply cannot see. Diversity here is not optics. It is methodology.
How the right room changes everything: a Scout example
A client came to us with an advisory board planned around a rare disease diagnosis programme. On paper the guest list looked strong: experienced specialists, leading referral centres, a sharp clinical question. Before the meeting, Scout conducted a landscape analysis and a KOL mapping that revealed a structural blind spot. Every planned invitee worked in highly specialised settings — centres that patients had already navigated the system to reach. The map looked comprehensive, but it was only showing one part of the pathway. We flagged this and recommended adding a clinician from a smaller, non-specialist setting — someone who saw the pathway from the other end.
The discussion guide we developed reflected this deliberately. Rather than opening with optimisation questions about what happens once patients arrive, we built in an earlier layer of inquiry. Where do patients come from before they reach you? At what point does recognition typically happen, and what gets in the way? What does the journey look like for the patients who never make it to a specialist at all? Those pre-framing questions created the conditions for something to shift in the room. About an hour in, the clinician from the non-specialist setting said something simple:
“Most patients never make it to you.”
That one comment reframed the entire discussion. The board’s output moved from incremental optimisation at the specialist level to something more fundamental: a redesign of how recognition happens much earlier in the pathway. Same topic, same clinical question, completely different answer. The insight did not come from the data alone. It came from designing the right conditions for it to emerge.
Design for conversation, not presentation
The most effective advisory boards feel slightly messy, in a good way. Short inputs lead to long discussions. Real cases replace abstract concepts. Breakout moments give people space to actually think. In diverse groups, not everyone enters the conversation at the same speed, and some of the most valuable perspectives arrive a few beats later if you give them the room to. If your agenda is tightly packed, it is probably too tight. The interesting things tend to surface in the space you leave, not the time you fill.
Ask better questions, then stop talking
Most advisory boards fall into the trap of leading questions that quietly steer people toward the answer the sponsor was hoping for. Better alternatives sound like this: what are we missing? Where would this fall down in real life? Who would this not work for? If this failed, why would it fail? Then let the silence do its job. In more diverse groups that pause matters even more, because it gives space for perspectives that might otherwise stay unspoken. Some of the best insights arrive right after that slightly awkward moment most facilitators rush to fill.
Close the loop, or do not bother opening it
An advisory board that ends in a summary slide deck is a missed opportunity. Share what you heard. Show what you are changing as a result. Keep the conversation going. And if different perspectives led to different conclusions, reflect that back rather than smoothing it over. Alignment is not always the goal. Understanding the full range of realities is. The boards that generate the most lasting value are the ones where experts leave feeling their time was genuinely useful, and where sponsors leave with something they did not already know.
A final thought
A well-run advisory board will not give you all the answers, but it will give you something better: a clearer view of where you might be wrong and for whom. In pharma, that is often the difference between a strategy that works on slides and one that works in the real world. Getting there takes more than a good guest list. It takes the right question, the right room, and a discussion guide built to surface what you do not yet know.
At Scout, we combine KOL mapping, strategic discussion design, and deep therapeutic expertise to ensure your advisory boards generate insight you can actually use. If you are planning a board and want to talk through the design, we would love to hear from you.
By Simon Rosenberg, Director of Research, Scout
Simon.Rosenberg@scoutdata.co.uk
